LY4052031 Clinical Trials (2026): 1 Studies for Advanced Solid Tumor & Bladder Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 LY4052031 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Advanced Solid Tumor & Bladder Cancer) and 420 total planned enrollment. 1 LY4052031 clinical trial is actively recruiting at 16 U.S. sites across 11 states. Most recent activity: NCT06465069 (May 2027).
Where to Participate: All LY4052031 Trial Sites in the U.S. (16 sites across 11 states)
Every actively recruiting LY4052031trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | City of Hope National Medical Center | Duarte91010-0269 | NCT06465069 | Map |
| CA | UCLA Department of Medicine-Hematology/Oncology | Los Angeles90024 | NCT06465069 | Map |
| CO | Sarah Cannon Research Institute at HealthOne | Denver80218 | NCT06465069 | Map |
| IL | University of Chicago Hospital | Chicago60637 | NCT06465069 | Map |
| IN | IU Simon Cancer Center | Indianapolis46202 | NCT06465069 | Map |
| MA | Massachusetts General Hospital | Boston02215 | NCT06465069 | Map |
| MI | START Midwest Cancer and Hematology Centers of W Michigan | Grand Rapids49546 | NCT06465069 | Map |
| MO | Washington University School of Medicine in St. Louis | St Louis63110 | NCT06465069 | Map |
| NY | Columbia University Irving Medical Center | New York10032-3729 | NCT06465069 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029-6574 | NCT06465069 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06465069 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT06465069 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030-4000 | NCT06465069 | Map |
| TX | South Texas Accelerated Research Therapeutics (START) | San Antonio78229 | NCT06465069 | Map |
| UT | University of Utah - Huntsman Cancer Institute | Salt Lake City84112 | NCT06465069 | Map |
| UT | START Mountain Region | West Valley City84119 | NCT06465069 | Map |
LY4052031 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting LY4052031 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06465069 | NEXUS-01A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | P1 | Metastatic Solid Tumor | 420 | Jul 2024 |
All LY4052031 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06465069 | NEXUS-01 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | P1 | recruiting | 420 | Eli Lilly and Company | Jul 2024 |
LY4052031 clinical trials: frequently asked questions
- How many LY4052031 clinical trials are there?
- 1 LY4052031 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are LY4052031 clinical trials recruiting in 2026?
- Yes — 1 LY4052031 trial is actively recruiting in 2026, with 16 U.S. sites across 11 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is LY4052031 being studied for?
- LY4052031 is being studied for Advanced Solid Tumor, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma and 9 more. The trials are grouped by indication on this page.
- What phase is LY4052031 in?
- LY4052031 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors LY4052031 clinical trials?
- The lead sponsor across the most LY4052031 trials is Eli Lilly and Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming LY4052031as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: